TGR5 MODULATORS AND METHODS OF USE THEROF
    5.
    发明申请
    TGR5 MODULATORS AND METHODS OF USE THEROF 有权
    TGR5调制器及其使用方法

    公开(公告)号:US20100152151A1

    公开(公告)日:2010-06-17

    申请号:US12622123

    申请日:2009-11-19

    摘要: The invention relates to compounds of Formula A: or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.

    摘要翻译: 本发明涉及式A的化合物:或其盐,溶剂化物,水合物或前药。 式A的化合物是可用于治疗各种疾病的TGR5调节剂,包括代谢疾病,炎性疾病,肝脏疾病,自身免疫性疾病,心脏病,肾脏疾病,癌症和胃肠道疾病。

    Formulations
    6.
    发明授权
    Formulations 失效
    配方

    公开(公告)号:US07691835B2

    公开(公告)日:2010-04-06

    申请号:US11835367

    申请日:2007-08-07

    申请人: James M. Frincke

    发明人: James M. Frincke

    IPC分类号: A61K31/56

    摘要: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.

    摘要翻译: 本发明提供了治疗诸如前列腺癌或改善与前列腺癌相关的一种或多种症状的病症或调节雄激素受体生物学活性的药物的方法。 本发明还提供适用于治疗应用的方法和组合物。

    Process and intermediates for the production of 7-substituted antiestrogens
    8.
    发明申请
    Process and intermediates for the production of 7-substituted antiestrogens 有权
    用于生产7-取代的抗雌激素的方法和中间体

    公开(公告)号:US20050101583A1

    公开(公告)日:2005-05-12

    申请号:US10398924

    申请日:2001-10-09

    摘要: A process for preparing an intermediate compound of formula (II) where X is as defined in the specification, R1 is haloalkyl, alkyl, alkenyl, cycloalkyl, carboxyalkyl, alkoxycarbonylalkyl, aryl or arylalkyl; R2, R3, R4 and R5 are organic groups as defined in the specification, which process comprises aromatisation of a compound of formula (III) where R1, R2, R3, n, X and R5 are as defined in relation to formula (II) and R4′ is a group R4 or a precursor group thereof, and thereafter if necessary or desired, carrying out one or more of the following steps: (i) removing any hydroxy-protecting groups R; (ii) converting a precursor group R4′ to a group R4, or where R4′ is a group R4, converting it to a different such group. Compounds obtained are useful intermediates for example in the preparation of fulvestrant. Novel intermediates are also claimed.

    摘要翻译: 制备其中X如说明书中所定义的式(II)的中间体化合物的方法是卤代烷基,烷基,烯基,环烷基,羧基烷基,烷氧基羰基烷基,芳基或芳基烷基; R 2,R 3,R 4和R 5是说明书中定义的有机基团,该方法 包括式(III)化合物的芳构化,其中R 1,R 2,R 3,R 3,n,X和R 5 如式(II)所定义,并且R 4'是基团R 4或其前体基团,然后如果需要或需要, 进行一个或多个以下步骤:(i)除去任何羟基保护基团R; (ii)将前体基团R 4'转化成基团R 4,或其中R 4'是基团R 4 ,将其转换为不同的这样的组。 获得的化合物是例如制备氟维司群的有用的中间体。 还要求新的中间体。